MC0553: A phase II safety and efficacy study with the VEGF receptor tyrosine kinase inhibitor pazopanib in patients with metastatic urothelial cancer

R. Pili; R. Qin; P. J. Flynn; J. Picus; M. Millward; W. M. Ho; H. C. Pitot; W. Tan; C. Erlichman; U. N. Vaishampayan

MC0553: A phase II safety and efficacy study with the VEGF receptor tyrosine kinase inhibitor pazopanib in patients with metastatic urothelial cancer

R. Pili, R. Qin, P. J. Flynn, J. Picus, M. Millward, W. M. Ho, H. C. Pitot, W. Tan, C. Erlichman, U. N. Vaishampayan

Research output: Contribution to journal › Abstract/Meeting Abstract › peer-review

9 Citations (Web of Science)

Original language	English
Number of pages	1
Journal	Journal of Clinical Oncology
Volume	29
Issue number	7
Publication status	Published - 1 Mar 2011
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@article{73070dc945d14134b5a7478399808672,

title = "MC0553: A phase II safety and efficacy study with the VEGF receptor tyrosine kinase inhibitor pazopanib in patients with metastatic urothelial cancer",

author = "R. Pili and R. Qin and Flynn, {P. J.} and J. Picus and M. Millward and Ho, {W. M.} and Pitot, {H. C.} and W. Tan and C. Erlichman and Vaishampayan, {U. N.}",

year = "2011",

month = mar,

day = "1",

language = "English",

volume = "29",

journal = "Journal of Clinical Oncology",

issn = "0732-183X",

publisher = "American Society of Clinical Oncology",

number = "7",

}

TY - JOUR

T1 - MC0553

T2 - A phase II safety and efficacy study with the VEGF receptor tyrosine kinase inhibitor pazopanib in patients with metastatic urothelial cancer

AU - Pili, R.

AU - Qin, R.

AU - Flynn, P. J.

AU - Picus, J.

AU - Millward, M.

AU - Ho, W. M.

AU - Pitot, H. C.

AU - Tan, W.

AU - Erlichman, C.

AU - Vaishampayan, U. N.

PY - 2011/3/1

Y1 - 2011/3/1

UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=uwapure5-25&SrcAuth=WosAPI&KeyUT=WOS:000208880700259&DestLinkType=FullRecord&DestApp=WOS

M3 - Abstract/Meeting Abstract

SN - 0732-183X

VL - 29

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

IS - 7

ER -

MC0553: A phase II safety and efficacy study with the VEGF receptor tyrosine kinase inhibitor pazopanib in patients with metastatic urothelial cancer

UN SDGs

Other files and links

Cite this